BLENOXANE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BLENOXANE is a small-molecule injectable chemotherapy agent approved in 1973 by Bristol Myers Squibb. The specific mechanism of action and approved indications are not provided in available data, but the product is positioned as a legacy injectable anticancer therapy. It is currently approaching loss of exclusivity.
LOE Approaching
As LOE approaches, the brand team is likely consolidating operations; expect smaller team size and focus on generic transition management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BLENOXANE offers limited career acceleration opportunities as a legacy product approaching LOE with zero linked job openings. Roles on this product focus on managing decline, generic transition, and operational efficiency rather than growth or innovation.
Supply Chain ManagerGeneric Transition Manager
Worked on BLENOXANE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.